Bolt Biotherapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.7M | $7.7M | $7.9M | $5.7M | $1.3M |
| Research and development | $28.5M | $57.5M | $61.5M | $73.1M | $75.7M |
| Operating expenses | $43.8M | $80.7M | $84.1M | $96.0M | $94.0M |
| Operating income | -$36.1M | -$73.0M | -$76.2M | -$90.3M | -$92.8M |
| Pretax income | -$33.4M | -$63.1M | — | — | — |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$33.4M | -$63.1M | -$69.2M | -$88.1M | -$98.6M |
| Balance Sheet | |||||
| Cash and equivalents | $11.7M | $7.2M | $10.8M | $9.2M | $27.4M |
| Current assets | $30.3M | $50.8M | $105.7M | $172.7M | $189.2M |
| Total assets | $56.7M | $99.6M | $159.8M | $227.8M | $307.7M |
| Current liabilities | $8.4M | $15.9M | $20.5M | $23.1M | $21.3M |
| Total liabilities | $30.2M | $42.4M | $47.0M | $56.3M | $57.6M |
| Stockholders' equity | $26.5M | $57.2M | $112.7M | $171.5M | $250.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$39.9M | -$61.3M | -$69.5M | -$76.5M | -$57.1M |
| Depreciation and amortization | $1.3M | $1.8M | $1.9M | $1.7M | $1.2M |
| Stock-based compensation | $2.8M | $7.4M | $9.2M | $9.6M | $8.5M |
| Capital expenditure | $72,000 | $41,000 | $206,000 | $2.0M | $2.3M |
| Free cash flow | -$39.9M | -$61.3M | -$69.7M | -$78.5M | -$59.4M |
| Impairments | $0 | $1.5M | $0 | $0 | $0 |
Shares outstanding 1.9M · Free float 90.6%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.